Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on ...

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

The Scottish Medicines Consortium, Scotland’s equivalent to the National Institute for Health and Clinical Excellence in England and Wales, has decided to back the use of Astellas Pharma’s Vesicare ...

Find clinical guidance on Vesicare LS, including indications, dosing, safety, side effects and evidence-based insights for healthcare professionals.

Hi Doc Thanks for the reply to my earlier question about taking Vesicare & Trepiline for my bladder problems. I would just like to please know could I not change the dosage of Trepiline to, say, 25mg ...

While nearly 33 million people in the US suffer from OAB (overactive bladder), due to stigma and embarrassment very few speak to their doctor about the condition. While nearly 33 million people in the ...

WALTHAM, Mass., April 3, 2008 Decision Resources, one ofthe world's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a drug's effect on the reduction of ...